Foralumab

Monoclonal antibody

Also known as NI-0401, TZLS-401

Phase 2topline reported

Evidence outlook

Multiple Sclerosis: topline reported 2026-11-02

The sponsor reported topline results on 2026-11-02 (Phase 2a INFORM-MS met its dual primary endpoints). The announcement is listed under Regulatory events.

Also in development:Secondary Progressive Multiple Sclerosis · Phase 2Amyotrophic Lateral Sclerosis · Phase 2

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (7)
Amyotrophic Lateral Sclerosis
Secondary Progressive Multiple Sclerosis
Other / comorbidity
NCT06868628 · Tiziana Life Sciences LTD
2025-05-19 – 2027-04-01 · Multiple System Atrophy
What this study did
NCT06489548 · Brigham and Women's Hospital
2025-09-16 – 2026-12 · Dementia, Alzheimers Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
What this study did
NCT04983446 · Tiziana Life Sciences LTD
2022-04-30 – 2022-12-30 · Covid19, COVID-19 Lower Respiratory Infection, COVID-19 Respiratory Infection
What this study did
NCT03291249 · Tiziana Life Sciences LTD
2017-12-01 – 2019-06-01 · NASH - Nonalcoholic Steatohepatitis, NAFLD, T2DM (Type 2 Diabetes Mellitus)
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT00805909 · Light Chain Bioscience - Novimmune SA
2007-08 – 2009-01 · Acute Renal Transplant Rejection
What this study did
NCT00630643 · Light Chain Bioscience - Novimmune SA
2006-01 – 2007-12 · Moderate to Severe Crohn's Disease
What this study did
Phase 1 (3)
Secondary Progressive Multiple Sclerosis
NCT05029609 · Tiziana Life Sciences LTD
2021-10 – 2022-12 · Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Multiple Sclerosis
What this study did
Other / comorbidity
NCT05028946 · Tiziana Life Sciences LTD
2022-05-01 – 2023-11-07 · Crohn's Disease
What this study did
NCT06879067 · Tiziana Life Sciences LTD
2018-11-12 – 2020-11-09 · Safety, Tolerability
What this study did

Competitive landscape

This drug's own stage for Amyotrophic Lateral Sclerosis: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Foralumab: this drugPhase 2Monoclonal antibodyCD3not yet gradedNo reviewed efficacy summary in this indication
Edaravone (Radicava ORS)ApprovedSmall moleculeReactive oxygen species (ROS)Weak signalFeatured results are safety only in this race
Tofersen (Qalsody)ApprovedRNA / oligonucleotideSOD1Partial signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesnot yet gradedNo reviewed efficacy summary in this indication
UlefnersenPhase 3RNA / oligonucleotideFUSReliable signal
NCT04768972: FUSION (NCT04768972): ulefnersen met its primary endpoint, a joint rank (win-ratio style) analysis of time to death/permanent ventilation, time to rescue, and change in ALSFRS-R score to Day 505 vs placebo; p=0.0005.
CB03-154Phase 2/3Small moleculeKCNQ2/3 (Kv7.2/7.3) potassium channel (opener)not yet gradedNo reviewed efficacy summary in this indication
CNM-Au8Phase 2/3Nanoparticlemitochondrial energy metabolismnot yet gradedNo reviewed efficacy summary in this indication
IbudilastPhase 2/3Small moleculePDE4 and PDE10; macrophage migration inhibitory factor (MIF)not yet gradedNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2/3Small moleculeDendritic spine densityWeak signalFeatured results are safety only in this race
DazucorilantPhase 2Small moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
ALN-SODPhase 1/2RNA / oligonucleotideSOD1not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Foralumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
Phase 2Multiple System AtrophyRecruiting
Est. primary completion 2027-04-01 · NCT06868628 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Amyotrophic Lateral SclerosisEnrolling by invitation
Est. primary completion 2027-07 · NCT07688239 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 November 2026Topline resultPhase 2a INFORM-MS met its dual primary endpoints